Literature DB >> 10084479

Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995.

A E Van Andel1, C Reisner, S S Menjoge, T J Witek.   

Abstract

STUDY
OBJECTIVE: To document temporal usage trends for commonly used respiratory medications in patients with COPD.
DESIGN: We retrospectively evaluated baseline concomitant medications of 3,720 patients with COPD enrolled in 10 bronchodilator clinical trials from 1987 to 1995. The proportion of patients in each trial using inhaled corticosteroids, inhaled beta-adrenergics, inhaled anticholinergics, oral theophylline, and oral corticosteroids was analyzed using the Cochran-Armitage trend test. PATIENTS: All patients had stable, moderate-to-severe COPD without evidence of asthma or atopy. Reversibility to beta3-agonists was not a requirement.
RESULTS: The percentage of patients using inhaled corticosteroids increased significantly over time (p < 0.001) from 13.2% in 1987 to 41.4% in 1995. The percentage of patients receiving oral theophylline decreased significantly (p < 0.001) over this same time interval (63.4 to 29.0%). In addition, the percentage of patients using oral corticosteroids and the percentage using oral beta-adrenergics decreased moderately (p < 0.05) (30.1 to 16.4% and 11.7 to 4.5%, respectively); the percentage of patients using inhaled anticholinergics increased slowly (p < 0.05) (48.2 to 53.8%). The percentage of patients receiving inhaled beta-adrenergics did not significantly (p > 0.05) change.
CONCLUSIONS: The observed changes in use of inhaled corticosteroids and theophylline were not likely related to differences in disease severity or other patient characteristics in the evaluated trials, but related to changing prescribing and COPD management practices.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10084479     DOI: 10.1378/chest.115.3.703

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

1.  Association between Inhaled Corticosteroid Use and Pulmonary Nontuberculous Mycobacterial Infection.

Authors:  Vincent X Liu; Kevin L Winthrop; Yun Lu; Husham Sharifi; Hekmat U Nasiri; Stephen J Ruoss
Journal:  Ann Am Thorac Soc       Date:  2018-10

Review 2.  Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease.

Authors:  Marcel Bonay; Catherine Bancal; Bruno Crestani
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Effect of theophylline on the rate of moderate to severe exacerbations among patients with chronic obstructive pulmonary disease.

Authors:  Marie-Christyne Cyr; Marie-France Beauchesne; Catherine Lemière; Lucie Blais
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

Review 4.  Oral theophylline for chronic obstructive pulmonary disease.

Authors:  F S Ram; P W Jones; A A Castro; J A De Brito; A N Atallah; Y Lacasse; R Mazzini; R Goldstein; S Cendon
Journal:  Cochrane Database Syst Rev       Date:  2002

5.  Pneumonia in elderly patients with chronic obstructive pulmonary disease.

Authors:  Pierre Ernst; Samy Suissa
Journal:  Curr Infect Dis Rep       Date:  2008-05       Impact factor: 3.725

6.  Treatment and quality of life in patients with chronic obstructive pulmonary disease.

Authors:  M Miravitlles; J L Alvarez-Sala; R Lamarca; M Ferrer; F Masa; H Verea; R Zalacain; C Murio; F Ros
Journal:  Qual Life Res       Date:  2002-06       Impact factor: 4.147

7.  Bronchoprotection in conscious guinea pigs by budesonide and the NO-donating analogue, TPI 1020, alone and combined with tiotropium or formoterol.

Authors:  D l Turner; N Ferrari; W R Ford; E J Kidd; B Nevin; L Paquet; P Renzi; K J Broadley
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

8.  Elevated placenta growth factor predicts pneumonia in patients with chronic obstructive pulmonary disease under inhaled corticosteroids therapy.

Authors:  Shih-Lung Cheng; Hao-Chien Wang; Shih-Jung Cheng; Chong-Jen Yu
Journal:  BMC Pulm Med       Date:  2011-09-30       Impact factor: 3.317

9.  The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease.

Authors:  Sang-Won Um; Chul-Gyu Yoo; Young Whan Kim; Sung Koo Han; Young-Soo Shim
Journal:  J Korean Med Sci       Date:  2007-10       Impact factor: 2.153

10.  Geographic differences in clinical characteristics and management of COPD: the EPOCA study.

Authors:  Marc Miravitlles; Cristina Murio; Gema Tirado-Conde; Gur Levy; Hana Muellerova; Joan B Soriano; Alejandra Ramirez-Venegas; Fanny W S Ko; Byron Canelos-Estrella; Eduardo Giugno; Miguel Bergna; Ivan Chérrez; Antonio Anzueto
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.